All In Biotech

Drug Trial Radar · NCT05334277

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

FurmOnertinib Mesylate With or Without Chemotherapy +/- bevacizUmab as firSt Line Treatment in Advanced Non-small Cell Lung Cancer Patients With Uncleared Epidermal Growth Factor Receptor (EGFR) Mutation Positive Circulating Tumor Cell DNA

Last checked: Nov 20, 2026Latest source record: Aug 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

May 6, 2022

Primary completion

Feb 28, 2025

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Allist Pharmaceuticals, Inc.; GeneCast Biotechnology Co., Ltd.
First posted
Apr 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported. This study aims to investigate the efficacy and safety of combination therapy compared with furmonertinib monotherapy in advanced EGFR mutant NSCLC with uncleared circulating tumor cell DNA.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • FurmonertinibDrug

    Furmonertinib 80mg QD

  • FurmonertinibDrug

    Furmonertinib 80mg QD

  • Furmonertinib/Pemetrexed/CarboplatinDrug

    Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.

  • Furmonertinib/Pemetrexed/Carboplatin/BevacizumabDrug

    Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: The primary analysis of Progression-free survival (PFS) based on investigator assessment will occur when PFS maturity is observed at approximately 34 months after the first patient begin study treatment

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, China · Not yet recruiting

  • Dongguan People's Hospital

    Dongguan, China · Not yet recruiting

  • Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang People's hospital

    Dongyang, China · Not yet recruiting

  • The First People's Hospital of Foshan

    Foshan, China · Not yet recruiting

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, China · Not yet recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China · Not yet recruiting

  • Sun Yat-sen University cancer center

    Guangzhou, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • Zhejiang Provincial Hospital of Chinese Medicine

    Hangzhou, China · Not yet recruiting

  • Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University

    Jiangmen, China · Not yet recruiting

  • Affiliated Jinhua Hospital, Zhejiang University School of Medicine

    Jinhua, China · Not yet recruiting

  • Mianyang Central Hospital

    Mianyang, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Not yet recruiting

  • Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute

    Shenyang, China · Not yet recruiting

  • Shijiazhuang People's hospital

    Shijiazhuang, China · Not yet recruiting

  • The Affiliated Cancer Hospital of Xinjiang Medical University

    Ürümqi, China · Not yet recruiting

  • The Third Affiliated Hospital of Wenzhou Medical University, Rui'an People's Hospital

    Wenzhou, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Not yet recruiting

  • Yijishan Hospital, Wannan Medical College

    Wuhu, China · Not yet recruiting

  • Tangdu Hospital, Fourth Military Medical University

    Xi'an, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Not yet recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.